<SEC-DOCUMENT>0001213900-22-031266.txt : 20220606
<SEC-HEADER>0001213900-22-031266.hdr.sgml : 20220606
<ACCEPTANCE-DATETIME>20220606080209
ACCESSION NUMBER:		0001213900-22-031266
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220606
FILED AS OF DATE:		20220606
DATE AS OF CHANGE:		20220606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NLS Pharmaceutics Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39957
		FILM NUMBER:		22996741

	BUSINESS ADDRESS:	
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		STATE:			V8
		ZIP:			CH-6370
		BUSINESS PHONE:		41-41-618-80-00

	MAIL ADDRESS:	
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		STATE:			V8
		ZIP:			CH-6370
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea161163-6k_nlspharma.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of June 2022 (Report No. 4)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-39957</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>NLS PHARMACEUTICS LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The Circle 6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>8058 Zurich, Switzerland</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Appointment of New Chief Financial Officer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 6, 2022, NLS Pharmaceutics
Ltd., or the Registrant, announced that Mr. Chad Hellmann has been appointed as its Chief Financial Officer, or CFO, effective June 6,
2022, until his duly qualified successor is appointed or until his earlier resignation or removal. Mr. Hellmann&rsquo;s annual base compensation
will be $160,000, he will be eligible for a bonus of up to $56,000, and he will be eligible to receive an option award under the Registrant&rsquo;s
existing Share Option Plan Regulation 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since 2014, Mr. Hellmann has
served as CFO and co-portfolio manager at Arcus Ventures. He also maintains an advisory role at Rosebank Capital Partners, where he co-created
the investment strategy for the long/short fund, which incorporates a liquid private equity approach for micro and small cap public companies
in the biotech and cleantech sectors. From 2004 through 2011, Mr. Hellmann served as CFO of Cat Trail Management, or CTM, a single-family
office and partner in Cat Trail Capital, or CTC, a private equity fund focused on technology, biotech and cleantech companies both in
the private and public markets. While at CTM, he led the firm&rsquo;s private equity fund investing in both debt and equity instruments,
where he managed several investments through the bankruptcy process both as a senior secured and subordinated unsecured lender. Additionally,
in this role, Mr. Hellmann acquired assets in the Chapter 7 process. Prior to CTC, he founded Bison Ventures, an early-stage venture capital
fund focused on investing in media and technology companies. Over the past 15 years, Mr. Hellmann has served on several boards of directors
including ET Water, Inc., NuVision, Inc. (Chairman), Vertebron Inc. and Yachtstore Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 31, 2022, Mr. Subhasis
Roy resigned as the Registrant&rsquo;s Interim CFO. Mr. Roy will continue to provide transition services to the Registrant through June
30, 2022. Mr. Roy&rsquo;s resignation was not as a result of any disagreement between Mr. Roy and the Registrant, or any matter related
to the Registrant&rsquo;s operations, policies or practices. The Registrant expresses its deep appreciation to Mr. Roy for his many contributions
to the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
June 6, 2022, the Registrant, issued a press release titled: &ldquo;NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer.&rdquo;
A copy of this press release is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Registrant&rsquo;s Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1783036/000121390022005236/ea154797-f3_nlspharma.htm">Form F-3</A>
(File No. 333-262489), filed with Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid">

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit<BR>
 Number</B></P></TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Document</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,239,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea161163ex99-1_nlspharma.htm">Press release titled: &ldquo;NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer.&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS Pharmaceutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 6, 2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea161163ex99-1_nlspharma.htm
<DESCRIPTION>PRESS RELEASE TITLED: "NLS PHARMACEUTICS APPOINTS CHAD C. HELLMANN AS CHIEF FINANCIAL OFFICER."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NLS Pharmaceutics Appoints Chad C. Hellmann
as Chief Financial Officer </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Switzerland/Zurich, June 6, 2022</B> - NLS
Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (&ldquo;NLS&rdquo; or the &ldquo;Company&rdquo;), a Swiss clinical-stage biopharmaceutical company
focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders,
announces that Chad C. Hellmann has been appointed to the position of Chief Financial Officer (&ldquo;CFO&rdquo;). Serving most recently
as CFO and co-portfolio manager of Arcus Ventures, Mr. Hellmann brings to NLS significant expertise in developing and implementing operational
strategies and capital markets solutions for life sciences companies. NLS also announces that Subhasis Roy has resigned as Interim CFO
and will remain a consultant to the Company through June 30, 2022 to assist with the CFO transition. NLS expresses its deep appreciation
to Mr. Roy for his many contributions to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Chad&rsquo;s diverse background as a CFO,
strategic advisor and investor brings important skills into the Company at the right time and should serve NLS well, as our Phase 2a results
for Quilience&reg; in the treatment of narcolepsy are fast approaching,&rdquo; said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics.
&ldquo;Key objectives for the Company are to evaluate and execute on creative strategies to advance Quilience and our pipeline of novel
compounds for central nervous system disorders, and we believe that Chad will be instrumental in helping us structure such initiatives
and maximize shareholder value. All of us at NLS extend a warm welcome to Chad.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Business
execution at NLS since its IPO in early 2021 has been impressive, and with the first prospective clinical trial results for Quilience
anticipated next quarter, I am excited to join the leadership team at this critical time,&rdquo; said Mr. Hellmann. &ldquo;The opportunity
for new narcolepsy treatments is compelling given that the disorder is substantially under-diagnosed and current therapies are suboptimal,
with most patients having to take multiple medicines to treat their symptoms. With its novel mechanism of action targeting the orexin
receptor, I believe that Quilience has potential to become a game-changing mono-therapy. This year promises to be an exciting one for
the Company and I am looking forward to helping NLS deliver on its next set of key milestones.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">Mr.
Hellmann joins NLS from Arcus Ventures, where he continues to consult as CFO and co-portfolio manager. He also maintains an advisory role
at Rosebank Capital Partners, where he co-created the investment strategy for the long/short fund, which incorporates a liquid private
equity approach for micro and small cap public companies in the biotech and cleantech sectors. From 2004 through 2011, Mr. Hellmann served
as CFO of Cat Trail Management (</FONT>&ldquo;<FONT STYLE="font-size: 10pt">CTM</FONT>&rdquo;<FONT STYLE="font-size: 10pt">), a single-family
office and partner in Cat Trail Capital (</FONT>&ldquo;<FONT STYLE="font-size: 10pt">CTC</FONT>&rdquo;<FONT STYLE="font-size: 10pt">),
a private equity fund focused on technology, biotech and cleantech companies both in the private and public markets.&nbsp;While at CTM,
he led the firm&rsquo;s private equity fund investing in both debt and equity instruments, where he managed several investments through
the bankruptcy process both as a senior secured and subordinated unsecured lender. Additionally, in this role, Mr. Hellmann acquired assets
in the Chapter 7 process.&nbsp;Prior to CTC, he founded Bison Ventures, an early-stage venture capital fund focused on investing in media
and technology companies. Over the past 15 years, Mr. Hellmann has served on several boards of directors including ET Water, Inc., NuVision,
Inc. [Chairman], Vertebron, Inc., and Yachtstore Ltd.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About NLS Pharmaceutics
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLS
Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing
and repurposing product candidates to treat rare and complex central nervous system disorders. The Company&rsquo;s lead product candidate,
Quilience&reg;, is a proprietary extended-release formulation of Mazindol (Mazindol ER) and is being developed for the treatment of narcolepsy,
and potentially other sleep-wake disorders such as idiopathic hypersomnia. Mazindol is a triple monoamine reuptake inhibitor and partial
Orexin-2 Receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. A
Phase 2a clinical trial evaluating Quilience</FONT><FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">in
adult subjects suffering from narcolepsy is currently ongoing in the United States. Previously, NLS successfully completed a Phase 2 study
in the U.S. evaluating Nolazol</FONT><FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">(Mazindol
Controlled-Release) in adult subjects suffering from ADHD. The study met all primary and secondary endpoints and Nolazol</FONT><FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">was well-tolerated. Quilience</FONT><FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">has received Orphan Drug Designations both in the U.S. and in&nbsp;Europe&nbsp;for
the treatment of narcolepsy. Up to 1/3 of narcoleptic patients are also diagnosed with ADHD. EAPs have great potential to benefit all
stakeholders involved, from the patient who receives the medicine early, to the pharmaceutical company who provides it. Although EAPs
can represent a significant undertaking, companies who invest in them should see considerable benefit in terms of launch preparedness,
relationship building and market penetration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release contains
expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements
when it discusses the expected timing of reporting the results for its clinical trial, its potential pipeline and ability to maximize
shareholder value and the belief that Quilience has potential to become a game-changing mono-therapy. These forward-looking statements
and their implications are based on the current expectations of the management of NLS only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following
factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes
in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical
trials; NLS&rsquo; products may not be approved by regulatory agencies, NLS&rsquo; technology may not be validated as it progresses further
and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge
is essential to the development of its products; unforeseen scientific difficulties may develop with NLS&rsquo; process; NLS&rsquo; products
may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical
settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS&rsquo; patents may not be sufficient;
NLS&rsquo; products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new
technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the
actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise
required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events
or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks
and uncertainties affecting NLS is contained under the heading &ldquo;Risk Factors&rdquo; in NLS&rsquo; annual report on Form 20-F for
the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC), which is available on the SEC&rsquo;s website,&nbsp;www.sec.gov,
and in subsequent filings made by NLS with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Contact </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alex Zwyer, CEO: +41 44 512 21 50</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations Contact </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cindy Rizzo: +1 908-229-7050</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pascal Nigen: +1 917-385-2160</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alpha Bronze, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.nlspharmaceutics.com</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ / # 2(  A$! Q$!_\0
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MM)0P]%4\+C%A5AYTW6Q5^:'Z^@A@&4@J0"""""",@@C@@CD$<$4M<O9V.G>
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MPF)H.*JTI1<ZM2A%7C)RJTG2C4@E&4FW&5>BNTG-*+>MJO\ U_7H=)17Y]_
MK]K+]HGXZ7'PZ\;:7^QSK/AS]G_XGS6]WH'Q#U[XO>#(/&>F^#M0@EN]'\=:
M_P##1+)KRTTW5[1;>X@T:UUFZUJWCO8#<0C#BO?_ (Q?&W7/ASXQ^&W@#PI\
M/9O'_BGXF'Q(=*MSXET_PQ8V,?ABSM;Z]DO+R_M+L$/!<YC$: YB*G)885;"
MUL/4]E5]G[2TKQA6HU>1P;C.-1TJDU"<)1DI0D^9-/=)LX,QS+!Y5A)8W'5)
MT\/&KAJ%Z=#$8FK.OC,13PN%HTL/AJ56O5J5\16I4J<*=.3<IJ[C&\E]"T5\
M@O\ M1WT'AKXU6^N_#K4/!/Q7^#G@F?QQ>>!M>U6TU73-9T26UNY-(UC2O$F
MBAH+W2;V[LI[.=E@@N[29#&\)<-L^C? GBI?%WA#P?X@N19V>I^)/"7A[Q+=
M:5!<"4V;:UI-GJ,D4:R%;A[>&2Y:**:2-2ZJI;#$BL7%K5][;KM=?)K5/8Y,
MOXARG-:_U; XIU:WU:>*E"=#$8>5*%+,:N55J-:&)IX>K0QE''T:E"M@ZU&&
M)IV524'3G3G/L:*JR7ME#/%:S7=K%<S_ .IMY+B))YN<?NH6<22<\?(IYJ62
M>&(,99HH@D;3.9)$0)$GWY6+$;8UR-SG"KW(J3V.:.OO1]UVE[T?==KVE[WN
MNVMI<KMK:VI+15>2[M(HVEENK>.)(UF>22:-(TA<X25G9@JQL>%D)"L> 32/
M>V<8MVDN[9!=LJVI>>)1<LP!5;<LX$S,""HCW$@@@$4 YP6\X*R3=Y15DVHI
MN\E9-M)/9MI)MM)V:*@N+JVLXC/=W$%K"" 9KB:."(%N%!DE94!)Z G)[5*C
MI*BR1NLD;J&1T8.CJPR&5E)5E(Y!!((Y!H'S1NX\RYDDW&ZYDGHFXWYDFTTF
MTDVFDW9CJ*K0WEG<O)%;W5M/)"<31PSQ2O$>F)$1V9#GC# &ECO+2:>:VANK
M:6YM\>?;QSQ//!G&/.B5C)%G(QO5<Y&*!*<':TX/F;4;2B^9J]U&TGS-6=TK
MM6=TK.UBBF++$RNRR1LL997974JC)]]7(.%*?Q D%>^*X'QY\3O"7PYA\*S^
M);R6)/&?C'P_X&T(6D27+3ZYXDFEATXS?O8U@L%,,CW5\S&*WC4$[F959I-Z
M)7;,L3BL-@Z%3$XJO2P^'I*+J5JTXPIP4ZM*A!RDVTE*M7HTHZ.]2K"*UEIZ
M#17"ZUXKUO3O%O@G0=*\&:AX@T+Q0=;_ +:\866J:5!IOA!=,LEN;%K^RN9E
MO]2&L7#&SM_[-23[,ZF6XQ'78SWMG:M&ES=VUN\QVQ+//%"TK?W8UD=2Y]E!
M-*WXA3Q-&K+$1C*2>&JQHU74IU*4/:3I4J\?9U*L*=.O!TZU/][0J5J2FY4G
M4]M"I3A9HJO/>6EJ8EN;JVMVG?RX%GGBA,S\?)$)&4R/R/E3<>1QS5B@V33;
M2:;C;F2:;5U=72;:NM5=*ZU5UJ%%%>)?M">-_BK\//A?K'BCX,?#(?%WQ[9W
MNDP:=X*.IKI0O;2\U"&WU"\^T$AG^P6KO.849&8 R%BD3JVV'H3Q6(HX:G*E
M&I7JPI0E7K4\/1C*;Y8NK7K2A2HTT_BJ5)1A!:R:0S\L/^"B'[*?[6GQE^/'
MA7Q=\)VOM?\ !R:)H^F^'DL?%<'AY/A[KMK/,VHZC<PSWUH\7VJ=H]3_ +:L
MXYY]@6Q)W6\,3_EA_P %A[?X@_"S]I[X;>)M?U.;5]2MO@K\/+#4]542)#K9
MTR&[TS6M0MBV-\J>(+.^NY(^'*7IE=%:45^Z'Q8_9J^/7BK]J'X8_M4O\:I?
MA]\,O OAC0=<\<?#C^U-=GGT&'0M*GOO%_A_3K/3D/A_7+#6'>?[??7ZI-N6
M<Q0.BVP;\N/V@_CO\#?^"P^L2_L_?#_PQXB^&'QL\,6WBG6?V?OB'XMDTZX\
M-^/K?3(!<Z[X.\3PZ8TFH>&[/Q'96D>IZ-<2?V@+*[MH9)O+=[B"3]3HS_MC
M*<JRS%K YAD>69!BJ&:8W*L%*AB\@Q&*KIX>>-KU9*.+JX:I@:>(JSP5.I2J
MT*E;%5H5$Y3EYV9Y?A\TP6(P.*BW2Q$5%ZKF3B[QG"]US0E:4;JSUB]),_3+
M_@D1\5O"_P 2OV4&NM+O[)M4T'QMK\7BF%)H_-MYKNUT^[LK^[YQ'%>6*8BE
MD(#"SF!(\LX_-#_@MK^V=^S!K_B/X1?L_>#I= ^(7QOL?%EQ<>(?&_AR]M[V
MS^&7A@Z5?27'A?4]5L?-M]3U3Q'J)T^;^PQ<3+HL5I)>W"0W-TJ'^=KXE_LV
M_MG_ +-&O:YX(\:_#;X[?#PSSR17Z^&H?&,GA+Q##&\L,-U;ZUX0DFT#6[*5
M=YM9'G9S#)@PQAV6N]_93_X)P?M<_M0?$CP_%X#^$?BGPUX?LKC=J?Q'^(.A
MZMX2\&>'Q=H\<VIW%WK%K:7FM3PVTD]Q!IVBVU]>7\ZK&I1F+CS\OX6P&4N.
M8U<ZHUZ&'BY4)TW2H4I1:DE.K46)J^T2A)MTJ46JDK1Y6K0/+64QI\/K(7&.
M(A2P4L'3E[+DYN3VCP]10?,H5*<I4Y2DI64X2G%I2:/VE_8,^%OQM^-7['W[
M;OASX%:O=:7XB\0:A\,=#T9XM3.AC7;K19KK6O%WANSUHRPKI]SJ_AJ\MM.>
MY,T,3BXCL[B>&"=W7]3/^"2'[.'[2?[/'P\^)EA\>Q>:#I7B7Q!HUWX&\ W^
MNP:Y<Z";&UOXO$&LXM+J]M-*CU^2?3HQ80W DD;2VO)X(VG1Y?B7]D+]O#]F
M#X/^(+?_ ()F?![2/B)HMWJVL>+?A+IW[3ERFE >*?CWJXO]"O\ QA/X8CD.
MJ:;I=SXLA^Q>'KAIG:SL['3DFM8+<&\KZ<_9S_9__;C_ .">/[-'QVU>+5!^
MVA\6=?\ &GAO5O ?PSM_%?B/[!:V!N_[.\2ZZ-7\5[-2.J:M:W8U74-'LC';
M*=+MC#<2227 ''FD\5*AF."JK"X*.8XO XC 4<;15/%8RC+DH*O#%.;H8:G3
M]E"=58F4*E&-7D?(IS3\'+N&<!@LSR;-XU,RQ-?*,MQ^"JRP^);P%/VDZU:<
M:F#4/;5JDWB*BA&A^[JRITZDX3G1I./[)>+_ /D4O%'_ &+NM_\ ILNJ_G3^
M!?AKQ/\ L^?LI_L6_P#!1/X8:?>ZC_PK[X>WOPX_:Q\':3$\L_Q!_9QN?B+X
MDQXJBLH<?;/%/P9OICXETN8I+/+H+:Q8NR6REX_Z*=#DU'Q%X0TF7Q7H@T/5
M=<\.6+^(_#GVM;U=)O\ 4M-B.KZ,+Z#8ETME/-<60NH@@F$?FH%W #F/AY\'
MOAS\*_AAI'P:\$^&;/3/AKH>D:AH.G^%KB2XU6Q71]5GO;G4=/N6U26[GO;:
M\DU&]$\=W+,)(YWB;,>%'RV#QT<'2JT90]K[3$T_;4[Q=*MA50Q&'Q%%S3>L
M_:1G2G%249TZ5:+O"/-^@Z22?=)JZ::O9JZ=FGKJG9IW3U3M_.Q/J.FZS_P2
MVTC5]%OH-4T?5_\ @H_'JFD:E:.LEMJ.EZC^U-=W>GWUO(I*R0W=I-#/$ZDJ
MR2 @X-?TK>*-"T'Q1X:U_P ->*K.SU'PSX@T;4M$\0:?J&W[#>Z-JEG-8ZE:
M7>\JH@N+2>6*0EEPKDA@0"/E]_V$/V63^S_'^R[%\,;>T^!\'B/_ (2RU\%6
M.O>)+**SUX:P^O1WUGJMMJT6LVK0:HYN;>.#4$B@(1(D2-%49'@#_@GU^RW\
M-;SQ'>>&_!OBB<>+O"&N> _$5EXD^*7Q/\6:7J?A;Q(D,6L:=+IGB3Q=J=E&
M]U';Q*M]!#%?VP!-K=0EF)Z,;C<%C$W&IBJ,J>-QN(HKV%.;G3Q$\&Z?-..(
M@J56"PTF[1G'GY>626L6DU]R7Y^7F?%>LZ+\7O\ @F#X@^ .A> ?B_??&7]D
MCXD_&3PG\#]+^!?Q+MK/4?BC\+(?',UW%X?E^$GCJR:UU3Q7X;\+M;JMSX9\
M165Y/8Z.TEPFILD"F/ZX_:83QD_[1W[*R^ )_#EOXJ\OXLG3Y?%EOJ-SH/EC
M0-*^UK>1:5-!?EFM]X@:"4;9MI8%>*VOA3_P3V_95^#OCG1OB-X5\!:QJ?B[
MPL9V\&ZCX\\?>//B-%X'>YB>WFG\&:?XW\1:[I_AJZ:V=K5;W2[:"]CMF,$5
MPD9*GWKXDV_PGT'5_"/Q2^(]WI^E:IX(FU2R\(ZO>WEW'-#=^);9+34+'3M,
MM'>36+V^MK=0EG#97MTL<,DL,2JDCCGQF(I8JK0=%5*^(Y*L:^(>&A0J8NI4
MDW3<Z%&512J4X.4:E9VJ5W)RFKQYY_.\4994S;*/JD,3'!J&9Y)CJF)EB'A7
M0P^6YO@L?B)4L2J=3V-?V.'FL/-PE%5W34M)'R_\1O@YXE\+_"[]IWXM_$GQ
M=8^+_B7XU^$&K>&Y'T'29-#\+>&_"FA:=J5WI^@Z+87%S>7ES_IMY<7EWJ6H
M7#7%S,_$42;E;R?Q5\+/"?PM^$W[+7Q@\%0:CIOQ-D\7_ K3]6\8/J^IW.K>
M(M)\76=G:ZYH>N/-=-!>:-<V\PM[?3O)6VL8(8(;6.-4Y_2"YM_"'Q8\"W5G
M,%U[P7XVT6YLKA"M[9+J6D:A');7,3+(MI?VWFH9(V#+!.ASPK"J.M_"OP+X
MB\+^&/!NL:&EWX<\&WWAG4?#FG&ZO(ETZ\\'B)?#TRS13I/,=/$,859Y)$FV
M_OUDR<\'-*+Y9)IJ;4HVM9*+@XM:;/1I[6[H^6S+@+#8J>*K9;#"2Y\CA2RS
M&8VOB,5C:.>5>*<-Q#7SEXZ:J5EB,12IR_VZE)8AU)0HTXTL(W2E^=_[0D?A
M[XH:?^T7XN\#?"7PL;WX40ZUI&N?&GQ7XSU;1/$-AXO\*:)%?N_@*PTV"^GM
MI?#[O:FWGGO=(L-1O1Y+6\JO(S[FM^'[?XT_%S]D_0_'EUJ>HZ#XN_9UUK6?
M&ND0ZC>V%OXO:WMO#VHI8ZX;*:":XL9M39+V]MED1;ID,$I,#NC?6NO_ ++O
MP1\3^)?$'BC6?!YN;SQ83+XGTZ/6M<M/#OB"^-M]E&JZOX;M-1AT6^U580BK
MJ$]DUSOBBE+F6-7'=:;\)? 6D:SX+U^QT,1:O\/O"]SX,\)WC7E]+)I?AR[C
MMHKC3PLEPT=R)([2W7SKI9KA1'E9068DYTDK7ND[7Z7@ENV]FKZ)):62:N>?
M_J+F^+S''8C,?[(EAL?C\JK8[#T)JGA\QHY=Q9CLW=2K@<-EF"A&5;),30R^
MI3QN)S3%8FO#&1QF.G@\5##Q^1O$?PO\'^/_ -L>Y\$^*K&XU+P1HO[-/AVZ
M3P=]OOH/#VH2VGCG4M,TY=6L;>XB&H0Z;;L7LX9W:-+A8YI%D:-<>->"?@7X
M"\3_  H_:B'B*+6];;X0^-_B_P"&/A))J.OZO-)\-=(\(Z<^N:%#X3<7:&PF
MMM1N!+)=-YMQ+'!!;-*+>,15^EG_  B7@FT^(G_"=M;V<'Q UCPM_P (E'>2
M7[I>WWAK3-1.L/96VG/<"*:*TOKG[3/<0VS2Q>:BRRB-E6L;PMX'^&C:%X]L
M/"]C;3:)\0/$GC"Y\;I;W5[)'JGB+57ET3Q:)7EF\RVE>2VELYH[0PQ0O&QM
MPIPQ%*25TI))4[NSM=2E=WM;WK-)WULUK9I=F(X!PV*QN(KXC#9-7GBLPXUK
MU55BYU*N$SC*,!A<BP]6+C[\<IQN'6,5"471R^I*CC,#"&+<<0?',_BS2?BA
MX%_9E^'OB'X;:;\9_BCXP^%-MX]BA\8:]<:'X6TK3++2=(T[6_%/B&YBBOFU
M2\NKVXMH(+*'2[V\:XFFN(VM5WN_@^G>*_&/A'X*_$[X='Q"O@SPU9_M;Z'\
M)M5U3PIK^I:G8_#CX>>*8]-O_$&G^&O$NI"+4K;2X+ZX.BVEU<""33%U.:WB
M\IXX\?HWXA_9N^$/B72/!&C7WARZM(?AUIRZ/X.O]%U[7="UK1]'$"6TND1Z
MWI.H6FISZ;<PQ1K=6ES<S13F-9'4R#=6?J7PQ_9Z^$GP^\<6.M>'/#GA_P"'
M/C+4+27QCIVJ+>7^CZMJ>HI8:'9J;*=[V9[Z_FCL888[&/[5<ZBR7$8:]?S3
M47S-0C&4Y2DN6"3;<N=M*,5?5IJR4=TT[K;S,9P5Q)7KRQ5?,<KPLJ62XC+:
MF:4\15P]2OAI\-9)EZH9@Z& PV88B/\ :F6X^>,Q^)SNK/ZEF4*N783!8NA4
MG6\P^*WPT\"_LY? OXP?$3X'>$;+PQXVL?AMJ=O;>(--DO[[4IH";>1]1N9;
MJZNOMUU;$'5/MTJRW)E@\WS&4LK>.^"?@I\0TN?@SXT^&_PP\&^"=0TO5_"V
MM^(_B79_%_4?$VJ?$#P=J-JG_"5P>)K=M MQXDEU^VNGU.![N\D%GJ<<$EH\
M<: 'ZJ^#/PA^!>BZ;=^)OA>USKNA^(]*NO#SO?\ B_Q+XLT==)6X"7VAQ:7X
M@U2_M=-2&X@^S7FGM:6]S;F)K.>.,*T5)H?[-_P1^&>J)XXTC2M5\/VWA8WV
MO6MD/&'BT^$?#ZPVUQ+=W5EX7DUB30[2WM[9KAUMX[ V\";C#"A"X5W%R@U/
MGYN5J49<S=N7D<&TTTW9)IZOX4[7[L1PAB<=B<JQT,!E.6Y=0PM*D\MR;-,+
MA\/E=6CG%'-99SEN,7#E2$ZV-HT(0Q3P<,JQTHX6G1J9EB,-B,5"'A/P<U:W
MM?@A^V,]YJ:P'2?B_P#M)>>]Y>;)--A>QWV8E::0-:HRD-;#*(2?W()KQ;Q=
MX'\(^+/V;_V%=6\3Z+;:S?W?Q!^"OA*ZO;^>\,TWAOQ VH2:QI4LB7,68-1>
MW@,TA_T@&-?*FCR<_<NJ?LS_  )\9>*;SXC7OA&*_O\ Q1':ZAJZ6^KZW:^'
M/$TK6RBSU;6O#=K?P:)JU\L#1/%>7MA+/N6.5RTB[JZS6_@9\,/$/PTTWX1Z
MKX:2X\":+'IR:-I:7^HP7.D2:0YDTN[TW5H+J/5+*^L69C;7L%VES&&91)M9
M@5SI/[2?,FU:UK1Y&M]=5?IVT9A5X(SK&9?7R_%PR2M0PV08K*,MY\1B,13Q
M]9\9X?BG"8O%TJV!E3P,*F%IRP$XP^O5</5J5*T9U<-.--^!_$+0-(\&?M"_
ML5^%/"]H-%\.:9_PNVSL=(M)K@6D-M#X$MI882LLTC3+'*[/'Y[2%&8E2#@U
MPG[.WPR^'_[0FD>-?BC\9M+C\??$9_BGXXT6\LM>O]0=/A[9>%?$EWIGAWPW
MH>D17D,6A01Z796.IF2.&.>_ENS<R2R*PK[&L_A#X#LKGX<WRZ5<W6H?"BVU
M>T\#ZAJ.KZMJ-_I<6O6"Z9JQGN[R\FGU.6\LD6&2;4WNY1C<CJ_S5Q?B?]F#
MX,>+/%EYXVO_  U>Z=XAU2>WN=<NO#7B7Q)X6@\0W-J4,%QK]CX?U73K+5KA
M1&B-<7D$DTL:B.61UXI<ZM:\D[6YEO\ %)M;W]ZZOKNK:H]"OPCF$LP>/>7Y
M)F&!EF53%_ZMXW$3AEU.G6X9X>R>A6A)Y=B,'+$Y/BLIQBP5.IETJ$L'C)5<
M-]2QC@X?-/[17@C_ (0CXC>(OCG\2/AW8?&?X*6GAKPQ:S6C:W<6?B7X+P:!
M(T>J:UX<T.XG@T_6;#4YIH=4U![*XM]>6>((LIMH0)?T)TV\M-0T[3[^P8O8
MWUE:WEFY#*7M+F".:W8J_P ZEH70X;YAG#<YKQ?Q?^S?\)?'?B67Q/XJT35-
M5NKH:6-2TJ7Q1XEC\+ZO_8L,%OI@U?PO%JJ:%J(MHK:W4K<V+I.8D:Y69@2?
M<HXTB1(HD6..-%CCC10B(B *B(J@*JJH"JH      %*33C%:W7R5NBM=J_=I
M*_57U/?R#),7E>;\0XJ=+"4,!FF)CBJ%.-6GC,?4Q<JU>IB:];&K 8+$1P4Z
M<J$<)EF+K9E++JD:\,)C*6 G1P=)]%%%0?6D-S;6]Y;SVEW!%<VMU#+;7-M/
M&DL%Q;SHT4T$T3ADEBEC9HY(W4HZ,RL""17X7_M5? 7X;?\ !+[X=^./VQ/V
M0?V<K_XC?&:XUVQ\/V.G:M?^)O%'ACX8^'_&-[)'XD\0:7X=T@-JD&E1(([*
M5%N)3 MW#$U]9V(ECD_=:OE'XR_"+]H/QM\>/V=_B!\-/VA9_AG\)/AQJ7B"
MY^,OPD3PU:ZK%\8;'4;:&/2[.75I7#Z:+!TF4$J1#YWVNWS<H!7K93CZV#JS
MI_673P5>+>/PDZV)I8;,*5",ZD<)B%AE*<E7DE2@[**E-*I)495$RWX'XQ?\
M%$_VP_\ @H!>_L&?LI?&KX3^ ?&_P1UKXK&[U#X\0>#_  _>ZOXI\#O%$Z>%
M+(+?:7=ZMX<\.^+)83K,%Y/:1WZP7&GZ3>SPO))Y^KK_ /P4*_X*%_L\?\$U
M?V<_C3XG_9[U#XI?''QQXRU'PUXCO_$7AC7K>XT[P1:23R^#_$?B[PGX5M;;
M4K#Q#XYMXX],L6-M8VJLD>HW-O)<7T"3?T;$ C! (/4'D'\*S-:M;^^T;5K+
M2M1.D:I>:;?6NFZL+>.[.EZA/:RQ6>HBUF_=7)L;EXKH6\O[N8Q>6_RL:ZX9
MS@O88;#3R/ 2IT<PK8N<G.LIU:-655QPDZL5[9TJ2JPCS.I/GAAZ:]G&3E*4
MM-W:DU=:>7W_ -:GYE_L^?\ !/']EW4OB!X _;CU/X&:M\.?COXRT?1?B?JW
MP_U/7KZ?PSX ^)/BC2X-4US4+/PQ(D<5GXAM-2O;N3,[+'9WSR72Z99:BK>5
M^H]?,/[(7PK^._P;^"VF>!_VC?CM-^T9\3K77O$FH7OQ+GT&'P[)=:/J>I27
M6BZ-]AA9MZZ/9L+<7,I$C[O* \J&(GZ>KS,PQ%;$8F:JXJ6+A0<J.'J>TK3I
MQP\)-TX4/K"C65&,6E!5(JHU!.I>6I-.G3II\D(PYGS248J-Y/>4N72[Z].R
M04445PF@4444 %?.WQ?\.>+(?B%\)?BCX?\ #$WCW3O )\86&M>$;.[T^UUJ
MW3Q7IME:6WBOPU'JT]IIM[J^DM926$]G/>V4TNE:K>-:7'FHT4OT316M&JZ,
M^=1C+W9PE&5TI0J0E3FKQ:E%N,G:46I1=FKZJ7-B\-'%T?8RG.G:I1K0J0Y'
M*%7#UH5Z,^6I&5.:C4@G*G4C*$XMQ=GRRA\-?&SPM\7/'FI+K>B>%?&JPZS\
M+;S2?A]ING^,+;PQ<_"WXO7&KRSV?B[Q?#8:U':75M#8FPF-]:2:]]EAT^^T
M?^SI1JS2F];?"?XJP?$Q?'DM[X@N-0B^/FD71N!XNO4T5O@])\,(](\16\'A
MDZB=)AT^^\81I?/IIL?MWVZ.'4(=FS>WVO174LPJ1IJE&E1C%0E3^%R;A+F3
MC>5W9J7O6_B2C&I/WT>7+(</4KRQ%3$XR=25:&(_B1A%5H>R:FHPLKJ5-^RO
M=4*=2I0I)4FCX)\%_![XU^'(;#4M/U/7=/\ %WB+X=?M Z7XKU76O&>H:Y80
M^+]4\:6VH?!J\:QNM1O+6W72='GU%+&71[:%=,LV-E< XCCK"\._"SXU:?\
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F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
